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ABSTRACT
The sphingosine kinase (SPK)/sphingosine-1-phosphate (S1P)
pathway recently has been associated with a variety of inflamma-
tory-based diseases. The majority of these studies have been
performed in vitro. Here, we have addressed the relevance of the
SPK/S1P pathway in the acute inflammatory response in vivo by
using different well known preclinical animal models. The study
has been performed by operating a pharmacological modulation
using 1) L-cycloserine and DL-threo-dihydrosphingosine (DTD),
S1P synthesis inhibitors or 2) 2-undecyl-thiazolidine-4-carboxylic
acid (BML-241) and N-(2,6-dichloro-4-pyridinyl)-2-[1,3-dimethyl-
4-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-hydrazinecar-
boxamide (JTE-013), specific S1P2 and S1P3 receptor antago-
nists. After local injection of carrageenan in mouse paw S1P
release significantly increases locally and decreases during the
resolution phase. Expression of SPKs and S1P2 and S1P3
receptors is increased in inflamed tissues. Administration of
L-cycloserine or DTD caused a significant anti-inflammatory
effect. By using different animal models we have also demon-
strated that the SPK/S1P pathway contributes to changes in
vascular permeability and promotes cell recruitment. The S1P
effect on cell recruitment results is receptor-mediated because
both JTE-013 and BML-241 inhibited zymosan-induced cell
chemotaxis without effect on vascular leakage. Conversely,
changes in vascular permeability involve mainly SPK activity,
because compound 48/80-induced vascular leakage was sig-
nificantly inhibited by DTD. In conclusion, the SPK/S1P path-
way is involved in acute inflammation and could represent a
valuable therapeutic target for developing a new class of anti-
inflammatory drugs.
Introduction
Sphingolipids are formed either via the metabolism of
sphyngomyelin, a constituent of the plasma membrane, or by
de novo synthesis (Hannun and Obeid, 2008). During the last
few years, it has become clear that sphingolipids, in addition
to being structural constituents of cell membranes, are
sources of important signaling molecules (Bartke and Han-
nun, 2009; Maceyka et al., 2009). Indeed, there are different
enzymatic pathways that result in the formation of various
lipid mediators, which are known to have important roles in
many cellular processes, including proliferation, apoptosis,
and migration. In particular, the sphingolipid metabolites,
ceramide and sphingosine-1-phosphate (S1P), have emerged
as a new class of potent bioactive molecules implicated in a
variety of pathophysiological processes (Chalfant et al.,
2005).
Several studies now suggest that these sphingolipid medi-
ators, including S1P, have an integral role in inflammation
(El Alwani et al., 2006; Snider et al., 2010). In particular, S1P
is involved in inflammatory-based diseases such as asthma
(Ammit et al., 2001; Roviezzo et al., 2007), rheumatoid ar-
thritis (Kitano et al., 2006) multiple sclerosis (Van Doorn et
al., 2010), and inflammatory bowel disease (Duan and
Nilsson, 2009). Furthermore, various sphingolipid enzymes
[sphingomyelinase, sphingosine kinase (SPK), etc.] are acti-
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vated by inflammatory cytokines, and their downstream lipid
mediators regulate inflammatory pathway in addition to im-
mune cell functions (Bartke and Hannun, 2009). In particu-
lar, SPKs, the enzymes responsible for the production of S1P
from sphingosine, have been shown to be modulated by a
plethora of stimuli, including ligands for G protein-coupled
receptors (S1P, bradykinin, muscarinic receptor agonist), ag-
onist of growth factor receptor (platelet-derived growth fac-
tor, vascular endothelial growth factor, epidermal growth
fact), transforming growth factor , tumor necrosis factor ,
and interleukins (Spiegel and Milstien, 2003; Taha et al.,
2006).
S1P signaling is the result of a complicated system of
regulation. To date, most S1P functions have been attributed
to receptor-mediated signaling. S1P exerts different cellular
effects depending upon the subtype of S1P receptors (S1Pn)
and the downstream G protein coupled. Other biological ef-
fects such as activation of Ras and extracellular signal-reg-
ulated kinase signaling pathways by vascular endothelial
growth factor or activation of phosphatidylinositol 3-kinase/
Akt have been shown to be linked to S1P intracellular action
because they cannot be reproduced by exogenous addition of
S1P (Chalfant and Spiegel, 2005).
Although it is clear that sphingolipids can be intimately
involved in the onset and maintenance of inflammation, it is
still unclear whether targeting sphingolipid action could rep-
resent a feasible anti-inflammatory therapeutic strategy.
There are now several compounds that have been developed
that can manipulate different component of the sphingosine
pathway, e.g., S1P synthesis inhibitor or selective S1P recep-
tors antagonists (Koide et al., 2002; Nishiuma et al., 2008;
Chiba et al., 2010; Imasawa et al., 2010).
Here, we have addressed the relevance of the SPK/S1P
pathway in the acute inflammatory response in vivo. We
have used drugs able to interfere with 1) S1P synthesis, by
pharmacological modulation with appropriate inhibitors or
2) S1P action, by using specific receptor antagonists. Our
study focuses mainly on the early stage of inflammation,
analyzing the SPK/S1P pathway contribution to vascular
leakage or cell infiltration by using different preclinical well
known models.
Materials and Methods
Materials. DL-threo-Dihydrosphingosine (DTD; an inhibitor of both
isoforms of SPKs), L-cycloserine (L-cycl; an inhibitor of sphingolipid
metabolism), and 2-undecyl-thiazolidine-4-carboxylic acid (BML-241)
(an S1P3 /S1P2 antagonist) were purchased from Vinci Biochem (Vinci,
Italy). N-(2,6-Dichloro-4-pyridinyl)-2-[1,3-dimethyl-4-(1-methylethyl)-
1H-pyrazolo[3,4-b]pyridin-6-yl]-hydrazinecarboxamide (JTE-013) (an
S1P2 antagonist) was purchased from Tocris Bioscience (Bristol, UK).
Anti-S1P1, anti-S1P2, anti-S1P3, anti-S1P4, anti-SPK1, and anti SPK2
were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Compound 48/80 (CM 48/80) and all other reagents were obtained from
Sigma-Aldrich (St. Louis, MO).
Animals. Male CD-1 mice (Harlan, Milan, Italy) weighing 20 to
25 g were separated into groups (n 6). All animal experiments were
approved by and performed under the guidelines of the Ethical
Committee for the use of animals, Barts and The London School of
Medicine and Home Office regulations (Guidance on the Operation of
Animals, Scientific Procedures Act, 1986), and the Animal Ethical
Committee of the University of Naples Federico II.
Sphingosine-1-Phosphate Measurement. Mice received sub-
plantar administration of 50 l of carrageenan (1% w/v) (Posadas et
al., 2004) or vehicle (saline). Mice were sacrificed with carbon dioxide
2, 4, or 6 h after carrageenan administration. Paws were cut and
centrifuged at 4000 rpm for 30 min. Exudates (supernatants) were
collected with 100 l of saline and used for S1P quantification by
using a commercially available enzyme-linked immunosorbent assay
kit (Echelon; Tebu-bio, Versailles, France).
Western Blot.Mice received a subplantar administration of 50 l
of carrageenan (1% w/v) or vehicle and were sacrificed after 2, 4, or
6 h. The injected paws were cut and used for Western blot analysis.
In brief, mouse paws were homogenized in 10 mm HEPES pH 7.4
buffer containing saccharose (0.32 M), EDTA (100 M), dithiothrei-
tol (1 mM), phenylmethylsulfonyl fluoride (1 mg/ml), and leupeptin
(10 g/ml) with a Polytron homogenizer (Kinematica, Littau-Lu-
cerne, Switzerland) (three cycles of 10 s at maximum speed). After
centrifugation at 3000 rpm for 15 min, protein supernatant content
was measured by Bradford reagent, and protein concentration was
adjust at 30 g. Protein samples were loaded on 10% SDS-polyacryl-
amide gel electrophoresis and transferred onto nitrocellulose mem-
branes for 45 min at 250 mA. Membranes were blocked in PBS-
Tween 20 (0.1%) containing 5% nonfat milk and 0.1% bovine serum
albumin for 30 min at 4°C. Membranes were washed with PBS-
Tween 20 (0.1%) at 5-min intervals for 30 min and incubated with
anti-S1P1 (1:1000; Santa Cruz Biotechnology, Inc.) anti-S1P2 (1:
1000; Santa Cruz Biotechnology, Inc.), anti-S1P3 (1:1000; Santa Cruz
Biotechnology, Inc.), anti-S1P4 (1:1000; Santa Cruz Biotechnology,
Inc.), anti-SPK1 (1:2000; Santa Cruz Biotechnology, Inc.), or anti-
SPK2 (1:2000; Santa Cruz Biotechnology, Inc.) overnight at 4°C.
Blots were washed with PBS-Tween 20 (0.1%) at 5-min intervals for
30 min and incubated with secondary antibody for 2 h at 4°C. The
immunoreactive bands were visualized using an enhanced chemilu-
minescence system (ECL; GE Healthcare, Chalfont St. Giles, Buck-
inghamshire, UK). Protein levels were evaluated through densitom-
etry (how intense the stain was) versus -actin.
Mouse Paw Edema. Mice were lightly anesthetized with enflu-
rane and received subplantar injection of 50 l of carrageenan (1%
w/v) (Posadas et al., 2004). Paw volume was measured using a
hydroplethismometer especially modified for small volumes (Ugo
Basile, Comerio, Italy) immediately before the subplantar injection
(basal value) and 2, 4, and 6 h thereafter.
Mice were divided into three groups (n  6) and received intra-
peritoneal administration of 1) L-cycl, a sphingolipid metabolism
regulator with inhibitory activity of serine palmitoyltransferase that
catalyzes the first step of sphingolipid biosynthesis (10–100 mg/kg in
200 l) 24 h and 30 min before the beginning of inflammation
(Williams et al., 1987), 2) DTD, an inhibitor of both isoforms of SPKs
(0.3–3 mg/kg), 30 min before inflammogen application (Nishiuma et
al., 2008), or 3) vehicle (DMSO/saline 0.1%). To assess the efficacy of
these drugs, in a separate set of experiment we evaluated S1P
release after inflammatory challenge in the presence of L-cycl and
DTD using the dose that was determined previously to give the
maximal response.
MPO Measurement. Mice from different groups were sacrificed
with CO2 after 2, 4, and 6 h from carrageenan injection. Injected
paws were cut, weighed, and homogenated in 1 ml of hexadecyltrim-
ethyl-ammonium bromide buffer using a Polytron homogenizer (two
cycles of 10 s at maximum speed). After centrifugation of homoge-
nates at 10,000 rpm for 2 min, supernatant fractions were assayed
for MPO activity using the method described by Bradley et al. (1982).
In brief, samples were mixed with phosphate buffer containing 1 mM
O-dianisidine dyhydrochloride and 0.001% hydrogen peroxide in a
microtiter plate reader. Absorbance was measured at 450 nm, taking
three readings at 30-s intervals. Units of MPO were calculated
considering that 1 U MPO  1 mol H2O2 split, and 1 mol H2O2
gives a change in absorbance of 1.13  102 nm/min.
Intravital Microscopy.Mice were divided into three groups (n
6) and received intraperitoneal administration of 1) L-cycl, an inhib-
itor of sphingolipid metabolism (30 mg/kg in 200 l) 24 h and 30 min
before the beginning of inflammation, 2) DTD, an inhibitor of both
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isoforms of SPKs (1 mg/kg) 30 min before inflammogen application,
or 3) vehicle (DMSO/saline 0.1%). Experiments began with intraperi-
toneal injections of 1 mg of zymosan (in 0.5 ml of sterile saline); 4 h
later, when neutrophil infiltration was maximal (Gavins and Chat-
terjee, 2004), the vascular mesenteric bed was prepared for micro-
scopic observation. Mice were anesthetized with diazepam (6 mg/kg
s.c.) and Hypnorm (0.7 mg/kg fentanyl citrate and 20 mg/kg fluani-
sone i.m.). Cautery incisions were made along the abdominal region,
and the mesenteric vascular bed was exteriorized and placed on a
viewing Plexiglas stage (Gavins and Chatterjee, 2004). The prepa-
ration was mounted on a Zeiss Axioskop FS (Carl Zeiss GmbH, Jena,
Germany) with a water immersion objective lens (magnification
40), and an eyepiece (magnification 10) was used to observe the
microcirculation. The preparation was transilluminated with a 12-V,
100-W halogen light source. A Hitachi (Tokyo, Japan) charge-coupled
device color camera (model KPC571) acquired images that were
displayed on a Sony (Tokyo, Japan) Trinitron color video monitor
(model PVM 1440QM) and recorded on a Sony superVHS video
cassette recorder (model SVO-9500 MDP) for subsequent offline
analysis. A video time-date generator (FOR.A video timer, model
VTG-33; Broadcast Store, Los Angeles, CA) projected the time, date,
and stopwatch function onto the monitor. Mesenteries were super-
fused with bicarbonate-buffered solution at 37°C (7.71 g/l NaCl, 0.25
g/l KCl, 0.14 g/l MgSO4, 1.51 g/l NaHCO3, and 0.22 g/l CaCl2, 0.22,
pH 7.4; gassed with 5% CO2/95% N2) at a rate of 2 ml/min. The
temperature of the stage was maintained at 37°C. This procedure
has no effect on rectal temperature or blood pressure (data not
shown). Red blood cell velocity was measured in venules by using an
optical Doppler velocimeter (Microcirculation Research Institute,
Texas A&MUniversity, College Station, TX). Venular blood flow was
calculated from the product of mean red blood cell velocity (Vmean 
centerline velocity/1.6) and microvascular cross-sectional area, as-
suming a cylindrical geometry. Wall shear rate was calculated by the
Newtonian definition: shear rate  8000  (Vmean/diameter). One to
three randomly selected postcapillary venules (diameter between 20
and 40 m, length at least 100 m) were observed for each mouse;
measurements were taken 5 to 10 min after exposure of the chosen
vessels.
Mouse Air Pouch.Mice were divided into five groups (n 6) and
received intraperitoneal administration of 1) L-cycl, an inhibitor of
sphingolipid metabolism (30 mg/kg in 200 l) 24 h and 30 min before
the beginning of inflammation, 2) DTD, an inhibitor of both isoforms
of SPKs (1 mg/kg in 200 l) 30 min before inflammogen application,
3) an S1P3 antagonist (BML-241; 0.3–3 mg/kg in 200 l intraperito-
neally) 30 min before inflammogen application, 4) an S1P2 antago-
nist (JTE-013; 0.3–3 mg/kg in 200 l intraperitoneally) 30 min before
inflammogen application (Koide et al., 2002; Jongsma et al., 2006;
Chiba et al., 2010; Imasawa et al., 2010), or 5) vehicle (DMSO/saline
0.1%). Mice were then lightly anesthetized with enflurane. Air
pouches were developed by subcutaneous injection of 2.5 ml of sterile
air into the back of mice (28–30 g). Three days later 2.5 ml of sterile
air was reinjected into the same cavity (Posadas et al., 2000). After
another 3 days (6 days after the first air injection), 1 ml of zymosan
(1% w/v) or vehicle (saline) was injected into the air pouch. After 4 h
from zymosan injection, when neutrophil infiltration was maximal
(Posadas et al., 2000), mice were sacrificed by CO2 exposure, and
exudate in the pouch was collected with 1 ml of saline and placed in
graduated tubes and centrifuged at 125g for 10 min. The pellet was
suspended in 500 l of saline, and total leukocyte count was evalu-
ated by optical microscopy in the cell suspension diluted with Turk’s
solution.
Mouse Vascular Leakage. Intradermal injection of CM 48/80
induces an acute increase in vascular leakage to plasma proteins
(Segawa et al., 2007). Mice were divided into five groups (n  6) and
received intraperitoneal administration of 1) L-cycl (30 mg/kg in 200
l) 24 h and 30 min before administration of CM 48/80, 2) DTD (1
mg/kg in 200 l) 30 min before administration of CM 48/80, 3) an
S1P3 antagonist (BML-241; 0.3–3 mg/kg in 200 l intraperitoneally)
30 min before administration of CM 48/80, 4) an S1P2 antagonist
(JTE-013; 0.3–3 mg/kg in 200 l intraperitoneally) 30 min before
administration of CM 48/80 (Koide et al., 2002; Chiba et al., 2010;
Imasawa et al., 2010), or 5) vehicle (DMSO/saline 0.1%). Anesthe-
tized mice were injected intradermally with 5 g of CM 48/80 dis-
solved in 50 l of physiological saline into their shaved back skin
immediately after an intravenous injection of a 0.5% Evans blue
solution (5 ml/kg). Animals were sacrificed 30 min later, and skin
was removed for a quantitative determination of the extravasated
dye. Evans blue was neutralized by 1 ml of 6 M KOH at 45°C for 6 h.
This extract was neutralized by 1 ml of 6 M HCl, and then 2 ml of
acetone was added. The extract was clarified by filtration, its absor-
bance at 595 nm was measured, and the extracted Evans blue con-
tent was then calculated from its calibration curve.
Statistical Analysis. Data are expressed as mean  S.E.M. The
level of statistical significance was determined by one- or two-way
analysis of variance (ANOVA) followed by Bonferroni’s t test for
multiple comparisons, using the Prism software (GraphPad Software
Inc., San Diego, CA).
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Fig. 1. S1P level is increased in inflamed tissues. A, injection of 50 l of
carrageenan (carr; 1% w/v) in the mouse paw causes an increase in paw
volume that peaks at 4 h and resolves after 6 h. , p  0.001 versus
vehicle (one-way ANOVA). B, S1P levels measured in paw exudates were
significantly increased at all times tested. , p  0.05; , p  0.001
versus vehicle (two-way ANOVA).
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Results
S1P Pathway Is Up-Regulated in the Carrageenan-
Injected Mouse Paw. Injection of carrageenan in mouse
paw causes a time-dependent edema (Fig. 1A). S1P levels
were significantly elevated in exudates harvested from
mouse paws peaking at 2 h and declining at 6 h (Fig. 1B). At
all time points, e.g., 2, 4, and 6 h, there was also a significant
increase in S1P2 (Fig. 2A) and S1P3 (Fig. 2B) receptors as
well as in SPK1 (Fig. 2C) and SPK2 (Fig. 2D). S1P1 and S1P4
levels were unchanged (data not shown).
S1P Synthesis Inhibition Reduces Mouse Edema De-
velopment. The involvement of S1P pathway in mouse paw
edema was confirmed by experiments of pharmacological
modulation. Treatment of mice with a sphingolipid biosyn-
thesis inhibitor, e.g., L-cycl (10–100 mg/kg), significantly re-
duced in a dose-dependent manner carrageenan-induced
edema (Fig. 3A). The S1P level in paw exudates was also
significantly reduced after L-cycl treatment (Fig. 3B). Myelo-
peroxidase activity was markedly reduced in mice treated
with L-cycl (30 mg/kg) at all time points tested (Fig. 3C).
Intraperitoneal administration of DTD (0.3–3 mg/kg), an
inhibitor of sphingosine kinases, to mice caused a signifi-
cant and dose-dependent edema reduction (Fig. 4A). S1P
levels in the exudates were also significantly reduced by
DTD (Fig. 4B). MPO activity was significantly inhibited
only at 2 h (Fig. 4C).
L-Cycloserine, but Not DTD, Inhibits Leukocyte Ex-
travasation. Intravital microscopy allows a direct visualiza-
tion of the microcirculation in inflammatory conditions.
Thus, we used this experimental approach to study in vivo
the effect of DTD or L-cycl on neutrophil trafficking after
zymosan exposure. L-Cycl (30 mg/kg) caused a significant
inhibition of neutrophil adhesion (Fig. 5A) and migration
(Fig. 5B), whereas rolling (Fig. 5C) was unaffected. Con-
versely, DTD (1 mg/kg) did not affect any of the parameters
measured (Fig. 5).
L-Cycloserine Significantly Affects Zymosan-Induced
Cell Chemotaxis, Whereas DTD Significantly Inhibited
Vascular Leakage. Administration of zymosan in the dor-
sal air pouch induces a recruitment of blood-borne leuko-
cytes, reaching its maximum at 4 h (Posadas et al., 2000).
L-Cycl (30 mg/kg) significantly inhibited the recruitment
(Fig. 6A) as well as reduced MPO activity in pouch skin
samples (Fig. 6B). On the other hand, DTD (1 mg/kg) was
ineffective on zymosan-induced cell recruitment and MPO
activity (Fig. 6B). These experiments further suggest that
different signaling pathways of S1P are involved into the
inflammatory response through different molecular targets.
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Fig. 2. Inflammation up-regulates S1P
pathway. Western blot analysis for S1P2
(A), S1P3 (B), SPK1 (C), or SPK2 (D) was
performed on paw tissues harvested from
mice injected with 1% carrageenan (Car)
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Intradermal injection of CM 48/80 (5 g) induced an acute
increase in vascular leakage (Fig. 6C). DTD (1 mg/kg) pre-
treatment significantly inhibited Evans blue extravasation
induced by CM 48/80 (Fig. 6C). Conversely L-cycl (30 mg/kg)
did not modify vascular leakage (Fig. 6C).
S1P2 and S1P3 Antagonists Block Cell Recruitment.
It is known that S1P chemotactic proprieties are receptor-
mediated, and, in particular, a key role is played by S1P2 and
S1P3. The specific antagonists JTE-013 (blocking S1P2; 1
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A, L-Cycl (10–100 mg/kg), administered to mice 24 h and 30 min before
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subplantar injection significantly inhibited paw edema development. ,
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(one-way ANOVA). C, DTD (1 mg/kg) significantly reduced MPO levels in
paw tissue at 2 h. , p  0.01 versus vehicle (two-way ANOVA).
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mg/kg) and BML-241 (blocking S1P2 and S1P3; 1 mg/kg)
inhibited in a dose-dependent manner the cell recruitment
provoked by zymosan (Fig. 7A). JTE-013 (1 mg/kg) or BML-
241 (1 mg/kg) did not inhibit Evans blue extravasation in
mouse skin induced by CM 48/80 (Fig. 7B).
Discussion
The aim of this article was to investigate the role played in
inflammation by S1P pathway in vivo in preclinical relevant
models. S1P is rapidly released during acute inflammation at
the site of injury and is actively involved in the onset of the
inflammatory response. Indeed, S1P level significantly in-
creases locally after inflammatory challenge and declines
when inflammation resolves. At the same time in the paw
there is a significant up-regulation of S1P2 and S1P3 recep-
tors and both sphingosine kinases. This pattern of expression
implies that the S1P pathway is involved in the onset and
development of an early inflammatory reaction. This hypoth-
esis is supported by the finding that treatment of mice with
DTD, a sphingosine kinase inhibitor, or L-cycloserine, a sph-
ingolipid metabolism inhibitor, before carrageenan adminis-
tration significantly inhibited the edema. DTD modulates
mainly vascular permeability, whereas L-cycloserine signifi-
cantly reduces cell recruitment. In fact, DTD abrogates the
first phase of edema that relies mainly on changes in vascu-
lar permeability (Posadas et al., 2000), whereas L-cycloserine
markedly inhibited MPO activity, which is an index of neu-
trophil infiltration.
MPO evaluation does not give dynamic information on
cellular trafficking but it is an indirect measure of cell infil-
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tration performed, in our experimental conditions, when the
response peaks. To further clarify the relevance of S1P sig-
naling in acute inflammation we used a dynamic assay, e.g.,
intravital microscopy. Intravital microscopy allows the iden-
tification of specific steps operating when a leukocytes leaves
the bloodstream and moves to the inflamed tissue. L-Cyclos-
erine significantly reduced cell adhesion and emigration,
whereas DTD did not significantly affect both cell adhesion
and emigration.
S1P has chemotactic activity (Roviezzo et al., 2004;
Hashimoto et al., 2008; Ishii et al., 2009; Harvey et al. 2010;
Thangada et al., 2010). To clarify whether this effect on adhesion
and migration was mediated by chemotactic action of S1P on
inflammatory cells, we used the mouse air pouch, a preclinical
experimental model that allows evaluating chemotaxis in vivo.
L-Cycloserine produced a marked inhibition of the cell re-
cruitment elicited by zymosan, whereas DTD was ineffective.
Thus, the sphingosine kinase pathway seems not to be es-
sential for neutrophil recruitment, as confirmed by the find-
ing that mice nullified for both sphingosine kinases displayed
normal neutrophil functions (Michaud et al., 2006).
These preliminary data confirm a key role for S1P in acute
inflammation but suggest different molecular mechanisms
underlying the anti-inflammatory action of L-cycloserine and
DTD. L-Cycloserine and DTD are widely used as S1P synthe-
sis inhibitors, interfering at different levels in sphingolipid
metabolism. The sphingolipid metabolic pathway has an in-
tricate network of reactions, e.g., S1P can be synthesized
through de novo pathway or through the hydrolysis of com-
plex lipids, especially sphyngomielin (Bartke and Hannun,
2009). Furthermore, the levels of the various S1P precursors
display great differences among different type of cells. These
observations lead us to speculate that L-cycloserine and DTD
could modulate different cellular sources of S1P and, in turn,
different downstream signaling.
To gain further insight into the role played by sphingosine
we used available S1P receptor antagonists. It is known that
the chemotactic action of S1P relies on receptor interaction
(Roviezzo et al., 2004; Hashimoto et al., 2008; Ishii et al.,
2009; Harvey et al., 2010; Thangada et al., 2010). S1P2 and
S1P3 antagonists significantly inhibited in vivo zymosan-
induced neutrophil accumulation. Thus, the S1P pathway is
involved in cell recruitment in acute inflammation through a
receptor-mediated mechanism. Our data also suggest that
the sphingosine kinase does not play a major role in cell
recruitment. However, its inhibition exerted a degree of anti-
inflammatory effect in mouse paw edema. This apparent
discrepancy could be explained by the specific role played by
SPK in vascular permeability. Indeed, DTD significantly inhib-
ited vascular extravastion in the skin assay, an animal model
specifically developed to evaluate vascular permeability. This hy-
pothesis is further corroborated by the fact that sphingosine ki-
nases are widely expressed on endothelium, and endothelial cells
are a key source of plasma S1P (Venkataraman et al., 2008).
In conclusion, our data demonstrate that S1P is an early
inflammatory mediator. The main events in acute inflamma-
tion in which the S1P pathway is involved are changes in
vascular permeability and cell recruitment. S1P exerts its
effect on cell recruitment by increasing leukocyte trafficking
through receptor-mediated mechanisms. On the other hand,
changes in vascular permeability are mediated mainly by
SPK activation. Therefore, selective antagonists of S1P2 or
S1P3 receptors as well as SPK inhibitors could represent a
feasible alternative therapeutic strategy to be developed for
modulating inflammatory-based diseases.
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